Thursday, October 2, 2025 10/2/2025

Chemical biology studies of MmpL3 inhibition and resistance in mycobacteria

Award Number: R01AI173285
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/13/2023
PERIOD OF PERFORMANCE END DATE: 06/30/2028

Group Awards By:

View Award Description

Chemical biology studies of MmpL3 inhibition and resistance in mycobacteria - MmpL3 (Mycobacterium membrane protein Large 3) is a common target of inhibitors of mycobacterial growth identified by whole cell, phenotypic, high throughput screens. MmpL3 is a mycolate flippase that moves trehalose monomycolate (TMM) to the pseudoperiplasmic space, from where TMM is modified to trehalose dimycolate (TDM) and incorporated into the mycomembrane. Mycobacterium tuberculosis (Mtb) and M. smegmatis mmpL3 knockdown strains show that mmpL3 is essential for survival both in vitro and in mice. This phenotype makes MmpL3 an attractive therapeutic target and supports efforts to characterize molecules targeting MmpL3. Multiple MmpL3 inhibitors exhibit synergistic interactions with TB drugs, further supporting interest in this target. Using an innovative combination of untargeted and targeted mutant screens, we have identified ten new and distinct scaffolds that inhibit MmpL3 function. These compounds are bactericidal both in vitro and against intracellular Mtb in primary murine macrophages. The inhibitors are mycobacteria specific with several showing activity against the non-tuberculous mycobacterial (NTM) species M. abscessus (Mab), including the HC2099 and HC2091 series. Pilot structure activity relationship (SAR) studies involving the synthesis of over 100 analogs of HC2099 and HC2091 have identified analogs with whole cell Mtb half-maximal efficacies of ~80 nM and ~280 nM, respectively. Several analogs exhibited high solubility, stability in microsomes and no cytotoxicity in macrophages, supporting their further development. For example, MSU-43085, an analog of HC2099, is orally bioavailable, active against Mtb in an acute murine model of infection and has activity comparable to standard of care drugs against Mab in vitro and in macrophages. Therefore, these series will be valuable tools to understand inhibitor-MmpL3 structure-function interactions and as leads for new TB drug development. Our library of MmpL3 inhibitors and mutants also will enable our team to define mechanisms of resistance in MmpL3. Cluster analysis of cross resistance profiles, generated by dose response experiments for each combination of 13 MmpL3 inhibitors against 24 different mmpL3 mutants, defined two clades of inhibitors and two clades of resistant mutants. Pairwise combination studies of the inhibitors revealed antagonistic, synergistic and additive interactions that were specific to the identified clades. Modeling of resistance substitutions to the MmpL3 crystal structure revealed clade specific localization of the residues to specific domains of MmpL3. These findings support our hypothesis that combinations of MmpL3 inhibitors or rationally designed molecules can be employed to reduce the frequency of resistance. The overall goals of this study are to: 1) optimize new MmpL3 inhibitors to define inhibitor MmpL3 interactions and generate proof-of-concept data showing efficacy in vivo (Aim 1); and 2) define mechanisms of resistance in MmpL3 to devise strategies to reduce the evolution of resistance and design more durable drugs (Aim 2).


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $729,894 )
2025	2025	MICHIGAN STATE UNIVERSITY	426 AUDITORIUM RD RM 2	EAST LANSING	MI	48824	INGHAM	USA	Allergy and Infectious Diseases Research	000	3	7/14/2025	NON-COMPETING CONTINUATION	$729,894
														Subtotal = $729,894

Issue Date FY: 2024 ( Subtotal = $747,825 )
2024	2024	MICHIGAN STATE UNIVERSITY	426 AUDITORIUM RD RM 2	EAST LANSING	MI	48824	INGHAM	USA	Allergy and Infectious Diseases Research	000	2	6/10/2024	NON-COMPETING CONTINUATION	$747,825
														Subtotal = $747,825

Issue Date FY: 2023 ( Subtotal = $758,959 )
2023	2023	MICHIGAN STATE UNIVERSITY	426 AUDITORIUM RD RM 2	EAST LANSING	MI	48824	INGHAM	USA	Allergy and Infectious Diseases Research	000	1	7/13/2023	NEW	$758,959
														Subtotal = $758,959

Grand Total All Awards = $2,236,678

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Chemical biology studies of MmpL3 inhibition and resistance in mycobacteria

Award Number: R01AI173285

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/13/2023

PERIOD OF PERFORMANCE END DATE: 06/30/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer